Lindus Health and Tiefenbacher Group Launch Virtual Clinical Trial for ME/CFS Treatment

Lindus Health, the self-described "anti-CRO" focused on faster and more reliable clinical trials, has joined forces with Tiefenbacher Group to launch a new clinical trial targeting Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS), a condition that affects approximately 1% of the population yet remains poorly understood.

The Phase 2 trial, named ReMEdi, will evaluate a therapeutic previously successful in treating symptoms of other fatigue-related conditions. Adopting a virtual model, the trial aims to overcome participation barriers for ME/CFS patients who often experience extreme fatigue, decreased cognitive function, pain, and dizziness.

Patient recruitment will occur primarily through social media advertising, with pre-screening handled via Lindus Health's proprietary eClinical technology platform, Citrus™. This platform will facilitate data capture through electronic patient reported outcomes and enable telehealth visits with the study team. Participants will wear Oura rings for continuous remote monitoring and use GripAble devices for hand grip testing.

"Symptoms of ME/CFS can drastically diminish quality of life, and we're humbled to have the opportunity to contribute to Tiefenbacher's efforts to rewrite the narrative for this patient population," said Meri Beckwith, co-founder of Lindus Health. "By leveraging our virtual site services and eClinical platform, we're making participation more accessible while ensuring the collection of high-quality data to propel ME/CFS research."

The collaboration highlights the growing trend toward more accessible clinical trials, particularly for conditions that limit patients' mobility and energy. Tiefenbacher Group, a global healthcare company providing solutions across the pharmaceutical value chain, sees this trial as an important step forward.

"ME/CFS can be incredibly debilitating, keeping people from doing their usual activities or even actively living their life," said Dr. Simon Bock, Project & Market Access Manager of Tiefenbacher Group. "ReMEdi showcases our dedication to identifying novel treatment strategies that can alleviate symptoms and improve patient outcomes. We're excited to be working with Lindus Health to help us better understand ME/CFS in our mission to bring a one-of-a-kind treatment to the hands of these patients."

Both companies emphasize their commitment to improving understanding of ME/CFS and developing treatments that enhance patient quality of life. Lindus Health brings its experience from clinical trials across the US, UK, and Europe, having raised over $80M from investors including Peter Thiel and Balderton, while Tiefenbacher Group contributes its pharmaceutical expertise as a family-owned company with more than 900 employees globally.

Click here for the original news story.